Erectile Function Durability Following Permanent Prostate BrachytherapyPage 639
A. V. Taira, G. S. Merrick, R. W. Galbreath, W. M. Butler, K. E. Wallner, B. S. Kurko, R. Anderson, and J. H. Lief
In the majority of men, potency preservation after brachytherapy is durable. However, post-treatment erectile function is closely related to pre-treatment function. Men with good pretreatment erectile function (EF) had 7 year potency preservation was 73.6% compared to 23% for men with borderline pre-treatment EF. Radiation dose to proximal penile structures strongly predicted for long term potency. Younger men and men with better pretreatment EF appear to tolerate higher proximal penile doses with less impact. For slightly older men and those with more limited pretreatment EF, limiting proximal penile dose appears to make a significant difference in long term potency preservation.
Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Carcinoma: 4 Year Results of a Prospective Phase II StudyPage 677
A. J. Fakiris, R. C. McGarry, C. T. Yiannoutsos, L. Papiez, M. Williams, M. A. Henderson, and R. Timmerman
This study offers mature prospective data for the use of stereotactic body radiotherapy in early stage NSCLC. Building upon the results of their institutional phase I trial, the authors developed a phase II study utilizing 60-66 Gy in 3 fractions (20-22 Gy/fx), in medically inoperable patients. The results for the 70 enrolled patients are presented here, with a median follow-up of 50.2 months. Excellent tumor control was achieved, while toxicity was observed in a minority of patients.
Combination of Vandetanib, Radiotherapy and Irinotecan in the LoVo human Colorectal Cancer Xenograft ModelPage 854
P. Wachsberger, R. Burd, A. Ryan, C. Daskalakis, and A. P. Dicker
Simultaneous inhibition of VEGFR and EGFR by the dual receptor tyrosine kinase inhibitor, vandetanib, in combination with irinotecan (CPT-11) is a potential therapy to enhance radiotherapy for colorectal cancer (CRC). Wachsberger et al. showed that the triple combination of vandetanib, CPT-11, and radiotherapy produced a marked improvement in response as observed by measurable shrinkage of tumors during the first week of treatment of a human colorectal xenograft model. This study suggests that concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy may be beneficial in CRC tumors of this type.
IMRT Optimization in a Quasi-Periodically Deforming Patient ModelPage 906
M. Söhn, M. Weinmann, and M. Alber
In the presence of geometric uncertainties, a static dose distribution is inferior to accumulating the dose in moving tissue elements. We demonstrate how an IMRT treatment plan can be optimized from this tissue-eye-view perspective. The work presents the implementation of probability-based 4D-IMRT lung planning with explicit optimization of the accumulated dose-to-moving-tissue. The method incorporates 4D-Monte Carlo dose calculation in multiple breathing geometries and dose-warping based on deformable registration. For free-breathing treatment, 4D-IMRT planning can provide substantially better and more homogeneous coverage of the moving target than static, margin-based planning, and offers an efficient alternative to gating. The approach can be generally applied for 4D-IMRT optimization in randomly deforming patient models.
FULL TEXT
Page 639